Regeneron Pharmaceuticals Inc - REGN STOCK NEWS

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and the Society for Science & the Public announced winners of the Regeneron Science Talent Search 2020, awarding over $1.8 million in prizes to young innovators. Lillian Petersen won the top prize of $250,000 for her tool predicting crop yields, addressing food insecurity. Other notable projects included machine learning algorithms and eco-friendly industrial burners, showcasing youth contributions to science. The competition highlighted the importance of research in solving global challenges.

Regeneron Pharmaceuticals (NASDAQ: REGN) awarded $1.8 million to finalists of the 2020 Regeneron Science Talent Search, recognizing outstanding research by high school seniors. The top award of $250,000 went to Lillian Petersen from New Mexico for her tool predicting harvests, addressing food insecurity. Other notable projects include machine learning algorithms and eco-friendly gas burners. The competition, held virtually for the first time due to the pandemic, fosters scientific innovation among youth and has historically produced renowned science leaders.

Regeneron Pharmaceuticals (NASDAQ: REGN) announced that BARDA has agreed to procure its investigational Ebola treatment, REGN-EB3, as part of national health emergency preparedness. REGN-EB3, currently under FDA Priority Review with a decision due by October 25, 2020, is expected to generate approximately $10 million in 2021 and an average of $67 million annually from 2022 to 2026 if approved. This follows promising results from the PALM trial, demonstrating superior efficacy in preventing Ebola-related deaths compared to existing treatments.

Regeneron Pharmaceuticals (NASDAQ: REGN) will report its Q2 2020 financial and operating results on August 5, 2020, before U.S. markets open. A conference call and webcast will be held at 8:30 AM ET on the same day. Investors can access the call by dialing (888) 660-6127 (U.S.) or (973) 890-8355 (International). Regeneron is a biotechnology leader focused on inventing medicines for serious diseases, with a robust pipeline developed through their proprietary VelociSuite® technologies. For more information, visit www.regeneron.com.

Regeneron Pharmaceuticals (NASDAQ: REGN) announced a $450 million contract with BARDA and the U.S. Department of Defense to manufacture REGN-COV2, its dual antibody cocktail for COVID-19. As part of Operation Warp Speed, the contract facilitates production ahead of regulatory approval, with initial doses expected as early as summer 2020. The agreement includes plans for bulk lot completion by fall 2020, potentially providing 70,000 to 300,000 treatment doses and up to 1.3 million prevention doses. If approved, doses will be distributed at no cost to the American public.

Regeneron Pharmaceuticals (NASDAQ: REGN) announced the initiation of late-stage clinical trials for REGN-COV2, an investigational antibody cocktail aimed at treating and preventing COVID-19. A Phase 3 trial will focus on uninfected individuals with close exposure to COVID-19 patients, enrolling 2,000 participants. Additionally, two adaptive Phase 2/3 trials will evaluate the treatment's effectiveness in hospitalized and non-hospitalized patients, expecting preliminary data later this summer. Regeneron collaborates with NIAID to expedite this dual-antibody initiative.

Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi announced the termination of the U.S. Phase 3 trial for Kevzara® (sarilumab) in COVID-19 patients on mechanical ventilation, as it failed to meet primary and key secondary endpoints. While minor positive trends were noted in critically ill patients on mechanical ventilation, these were not statistically significant and were offset by negative trends in patients not on mechanical ventilation. Adverse events were reported in 80% of Kevzara patients. Future details will be submitted for peer review, and a separate trial led by Sanofi is ongoing outside the U.S.

Regeneron Pharmaceuticals announced significant findings in a recent Science Translational Medicine publication regarding its CD28 costimulatory bispecific antibodies combined with Libtayo® (cemiplimab). This combination demonstrated enhanced anti-tumor activity, overcoming resistance to anti-PD-1 monotherapy and promoting long-term T-cell memory in preclinical models. Regeneron intends to initiate clinical trials for three different CD28 bispecifics by the end of 2020, with the first trial already underway for prostate cancer using REGN5678.

The FDA has approved a new 300 mg single-dose pre-filled pen for Dupixent (dupilumab), enhancing treatment accessibility for adults and adolescents aged 12 and older with chronic type 2 inflammatory diseases, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis. This user-friendly pen, featuring hidden needle technology and audio-visual feedback, will be available in Q3 2020. Regeneron and Sanofi continue to collaborate with the FDA for the 200 mg version, while ensuring support through their DUPIXENT MyWay program, impacting over 150,000 patients globally.